Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
September 14, 2024 11:52 am ET
Delayed at least 20 minutes

Latest news, events & financials

September 14, 2024

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

September 14, 2024

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

September 14, 2024

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

View all

September 18, 2024

Webcast

Bank of America 2024 Global Healthcare Conference

Add to Calendar Webcast

October 31, 2024

Earnings

Merck & Co., Inc. Q3 2024 Earnings Call

Add to Calendar

February 04, 2025

Earnings

Merck & Co., Inc. Q4 2024 Earnings Call

Add to Calendar

April 24, 2025

Earnings

Merck & Co., Inc. Q1 2025 Earnings Call

Add to Calendar

View all

2Q24 Merck Earnings Announcement
PDF

2Q24 Merck Other Financial Disclosures
PDF

View all

Bank of America 2024 Global Healthcare Conference

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

80+

Phase III programs

30+

Under review

10+

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our Impact Report 2023/2024

Download our Sustainability financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q1 2024 earnings report

Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […]

Next: Our Q1 2024 earnings report